Sara Heebøll

MD, PhD

Curriculum Vitae

Profile photoSara Heebøll
Aarhus University Hospital
Department of Endocrinology and Internal Medicine
Steno Diabetes Center Aarhus
Palle Juul-Jensens Bvd
8200, Aarhus N
Denmark
E-mail: sara.heeboell@clin.au.dk
Phone: (+45) 27338050

Personal information

Born: February 23rd 1979
Spouse: Morten Andersen, MD
Children: Sigrid (born January 2009), Kirstine (December 2010), Marie (November 2013).
Residential address
Nedergårdsvej 36
8200 Aarhus N
Denmark

Education

Summer 2000 - winter 2008
Medicine, Aarhus University

2000
High school graduation, major in mathematics, fysics and chemistry

1999
High school graduation, major in linguistics

Clinical positions (post-graduate)

Feb 2017 - Recidency/specialist training in Internal Medicine/Endocrinology
2016-feb 2017Recidency in Endocrinology and Internal Medicine, Aarhus University Hospital
2015-2016Recidency in Clinical Biochemistry, Aarhus University Hospital
2010Recidency in Hepatology and Gastroenterology, Dept of Hepatology, Aarhus University Hospital
Apr 2008-May 2009Internship in Northern Jutland (internal medicin, urology and GP)

Research activity

September 2011 - present (defence August 2015)
PhD study: ’Effect of Resveratrol on non-alcoholic fatty liver disease – Translational studies’.
Supervisors: PhD Henning Grønbæk, PhD Karen Louise Thomsen, Professor Steen Bønløkke Pedersen.


Publications

(only 1st authorships)

14. Heebøll S, Vilstrup H Grønbæk H. Nye guidelines og nye behandlingsmuligheder for non-alkoholisk fedtlever sygdom. UfL


13. Heebøll S, Poulsen MK, Ornstrup MJ, Kjær TN, Pedersen SB, Nielsen S, Grønbæk H, Handberg A. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls. Int J Obes. 2017 Feb;41(2):262-267. doi: 10.1038/ijo.2016.223. PMID: 27916988

12. Placebo-controlled, randomized clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease.
Heebøll S, Kreutzfeldt M, Hamilton-Dutoit S, Poulsen MK, Stødkilde-Jørgensen H, HJ Møller, Jessen N, Thorsen K, Hellberg Y, Pedersen SB, Grønbæk H. Scandinavian Journal of Gastroenterology. 2016 Apr;51(4):456-64.

11. The effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment.
Heebøll S, El-Houri RB, Hellberg YE, Haldrup D, Pedersen SB, Jessen N, Christensen LP, Grønbæk H. J Gastroenterol Hepatol. 2015 Aug 27. doi: 10.1111/jgh.13151. [Epub ahead of print] PubMed PMID: 26312773.

10. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
Heebøll S, Thomsen KL, Clouston A, Sundelin EI, Radko Y, Christensen LP, Ramezani-Moghadam M, Kreutzfeldt M, Pedersen SB, Jessen N, Hebbard L, George J, Grønbæk H. Pharmacol Res. 2015 May-Jun;95-96:34-41. doi: 10.1016/j.phrs.2015.03.005. PubMed PMID: 25814186.

9. 'Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease.' Review.
Heebøll S, Thomsen KL, Pedersen SB, Vilstrup H, George J, Grønbæk H. World J Hepatol. 2014 Apr 27;6(4):188-98. doi: 10.4254/wjh.v6.i4.188.

8. 'Long-term effect of propranolol on portal hypertension in patients with cirrhosis: a single centre prospective experience'
Sara Heebøll, Gerda Elisabeth Villadsen, Niels Kristian Aagaard, Henning Grønbæk, Hendrik Vilstrup, Susanne Keiding. Scand J Gastroenterol. 2013 Aug;48(8):969-73.

7. ’STATUSARTIKEL: Prognose og behandling af non-alkoholisk fedtleversygdom (NAFLD) og steatohepatitis (NASH)’.
Sara Heebøll, Konstantin Kazankov, Marianne Kjær Poulsen, Hendrik Vilstrup, Henning Grønbæk. Ugeskrift for Læger 2012;174:488-490.

6. ‘SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumor recurrence and dedifferentiation’.
S Heebøll, M Borre, PD Ottosen, CL Andersen, F Mansilla, L Dyrskjøt, TF Ørntoft, N Tørring. Histol Histopathol. 2008 Sep;23(9):1069-76.

5. ‘Snail1 is over-expressed in prostate cancer’:
S Heebøll, M Borre, PD Ottosen, L Dyrskjøt, TF Ørntoft og N Tørring. APMIS 2009 Mar;117(3):196-204.

4. ‘Prostate cancer: To scan or not to scan for lymph node involvement?’
S Heebøll, J Solvig, M Borre. Scand J Urol Nephrol. 2007 Jul 27;:1-6. 1.

3. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
R Vergis, CM Corbishley, AR Norman, J Bartlett, S Jhavar, M Borre, S Heebøll, A Horwich, R Huddart, V Khoo, R Eeles, C Cooper, M Sydes, D Dearnaley, C Parker. Lancet Oncol. 2008 Apr;9(4):342-51.

2. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
KD Sørensen, PJ Wild, A Mortezavi, K Adolf, N Tørring, S Heebøll, BP Ulhøi, PD Ottosen, T Sulser, T Hermanns, H Moch, M Borre, TF Ørntoft , L Dyrskjøt. Clin Cancer Res. 2009 Feb 15;15(4):1400-10

1. Smarcc1 expression: A significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure.
RL Hansen, S Heebøll, PD Ottosen, L Dyrskjøt, M Borre. Scand J Urol Nephrol. 2011 Mar;45(2):91-6.

Presentations

9. 'Randomiseret, kontrolleret klinisk studie: Effekten af resveratrol på non-alkoholisk fedtlever'. 15 min. presentation at Dansk Selskab for Gastroenterologi og Hepatologi (DSGH)s årsmøde. September 2015.

8. 'Effect of Resveratrol Treatment on Experimental Non-Alcoholic Fatty Liver and steatohepatitis' 30 min. presentation at Resveratrol2014, 3rd International conference of resveratrol and health, Hawaii, USA. December 2014.

7. 'Effects of resveratrol treatment on experimental non-alcoholic steatohepatitis'. DSGH, 2014. Poster presentation.

6. 'Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience'. International Liver Congress, EASL, Amsterdam, 2013. Poster presentation.

5. 'LIRMOI 3: Resveratrol in Patients With Non-alcoholic Fatty Liver Disease'. PhD Day 2012. Poster presentation.

4. ‘‘Smarcc1 expression is significantly upregulated in prostate cancer’ Oral presentation, 26th Congress of the Scandinavian Association of Urology – NUF 2007, Aarhus 13.-15. Juni 2007. Awarded the JC Skou Prise for ‘best performance’.

3. ‘Smarcc1 expression is upregulated in prostate cancer’ Oral presentation, 7th World Basic Urological Research Congress, Dublin, 27.-29. september 2007.

2. ‘To scan or not to scan prostate cancer patients’ og ‘Are we to perform lymph node dissection on all prostate cancer patients?’ Oral presentation, 1. International Conference on Urogenital Disorders, Malmö, Sweden. 1.-3. september 2005.

1. ’Har lymfeknudestaging fortsat en plads i forbindelse med intenderet kurativ prostatacancer behandling?’ og ’Har eksisterende billeddiagnostik en plads i forbindelse med lymfeknudestaging ved prostatacancerbehandling?’ Oral presentation. Dansk Urologisk Selskabs Årsmøde, Herlev, Denmark. 8. april, 2005.

Foreign stays (relevant)

Sept 2012-Feb 2013
6 months phd studies at Storr Liver Unit, Westmead Hospital, Sydney, Australien.

1995-1996
Stay at high school in Morgantown, WV, USA.

Teaching experience

May 2015 -
Instructor of clinical biochemistry, medicin, Aarhus University, Denmark

April 2013 - 2015
Instructor at the phd course: 'Basic course in health sciences' og 'Preparing for the phd', Health, AU.

Sept 2011 –
Instructor of hepatology, medicin, Aarhus University, Denmark

Sept 2008 – June 2009
Instructor of internal medicin, Physial pherapists, UCN, Denmark.

Febr 2004 – June 2005
Instructor of makroskopic anatomy, Institute of Anatomy, Aarhus University, Denmark

Other scientific work

fall 2014 - 2015
Supervisor for research year student, medical student.
Project on regeneration after hepatectomy in rats with non-alcoholic fatty liver disease.

2020-
Supervisor for PhD student Indumathi Kumarathas in a project on fatty liver disease in patients with diabetes.

Guidelines
2018-2019 Participated in the National Clinical Guideline for the national health authorities (Sundhedsstyrelsen). ”NKR for tidlig opsporing og behandling af non-alkoholisk fedtleversygdom og non-alkoholisk steatohepatitis”

2016, 2019 Participated in the first clinical NAFLD guideline for the Danish Socielty for Hepatology and Gastroenterology (DSGH).

Courses and workshops

2015, JanAdvanced course in Laboratory Animal Science - Experimental surgical
2013, JuneResearch, Career, and Innovation - Developing your future career as a PhD. The transferable skills unit at AU.
2013, JuneGCP og researcher initiated clinical trials. The GCP unit, AU. ECTS 2.1
2013, AprClinical assessment of insulin resistance and other metabolic parameters. PhD skolen, AU. ECTS 1.6
2012, MayLipid and Adipose tissue metabolism. PhD school, AU. ECTS 1.4
2012, FebEASL School of Hepatology, Trieste, Italy. ECTS 1.4
2012, FebBasic Biostatistics, PhD school, AU. ECTS 7.0
2012, JanIntroduction to Stata, PhD school, AU. ECTS 0.7
2012, JanLaboratory Animal Science, PhD school, AU. ECTS 4.0
2011, NovTalent Development, PhD school, AU. ECTS 4.5
2011, NovWorkshop in Molecular Metab. and Endo. Ph.d. school, AU. ECTS 1.5
2011, NovMedical Scientific English 1. Ph.d. school, AU. ECTS 2.0
2010’Ph.d. Preparation’ Ph.d. school, AU. ECTS 1.0
2007'Introduction to Research in Health Sciences' and 'Literature search'
2007‘Immuncytochemistry og Immunhistochemistry’, MS Consult
2008-2011Miselaneous clinical couses and workshops

Volunteer work

January 2016
Union representative for junior MDs, Department of Clinical Biochemistry
Spring 2013 -
Serve as mentor in the national mentor-mentee arrangement for young doctors. Have mentee, who is trying to get into research.

Fall 2011 -
Board member of the PhD association at Health, Aarhus University. Organizes after work meetings on e.g. scientific misconduct, member of different advisory boards, organizes PhD Day and internationalization event.

May – Sept 2008
Union representative for young doctors at Dept of Medicine, Sygeghus Himmerland, Farsø.